DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC

DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC

Background The mammalian Notch family ligands delta‐like 3 (DLL3) is reported to be a potential therapeutic target for large cell neuroendocrine carcinomas (LCNEC). The effect of DLL3 expression on LCNEC prognosis has not yet been elucidated. Methods We reviewed the medical records of 70 LCNEC patie...

Full description

Bibliographic Details
Main Authors: Hiroyuki Ogawa, Yasuhiro Sakai, Wataru Nishio, Yusuke Fujibayashi, Megumi Nishikubo, Yuki Nishioka, Shinya Tane, Yoshitaka Kitamura, Tamotsu Sudo, Toshiko Sakuma, Masahiro Yoshimura
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Thoracic Cancer
Subjects:
Adjuvant chemotherapy
delta‐like 3
large cell neuroendocrine carcinoma
Online Access:https://doi.org/10.1111/1759-7714.13574

Internet

https://doi.org/10.1111/1759-7714.13574

Similar Items